Free Trial Information
BioCentury | Dec 17, 2020
Deals

GSK adds to next-generation checkpoint pipeline with Surface deal

...immunometabolism therapies —NZV930 targeting CD73 and SRF617...
Read More
BioCentury | May 21, 2020
Product Development

May 20 Quick Takes: Filgotinib meets in ulcerative colitis; broader labels for Lynparza, Tecentriq, plus updates from Eiger, eGenesis and more

...after announcing that it and Merck plan to evaluate a combination of Surface’s anti-CD39 mAb SRF617...
...#), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) filgotinib (GLPG0634, GS-6034) Sarasar, lonafarnib (mk-6336, sch 066336) SRF617 Keytruda...
Read More
BioCentury | May 24, 2019
Preclinical News

May 24 Preclinical Quick Takes: Baker-Garcia team controls cytokine receptor signaling; plus data from Surface, Innate, Moderna and Lyvgen

...in the adenosine pathway. Surface orally presented data for anti-CD73 mAb NZV930 and anti-CD39 mAb SRF617...
...triphosphate diphosphohydrolase 1; CD73 (NT5E) - Ecto-5’-nucleotidase; EpoR - Erythropoietin receptor Sandi Wong, Staff Writer IPH52, IPH5201 IPH53 LVGN6051 MRNA-1944 SRF373 (NZV930) SRF617 Innate...
Read More
BioCentury | Dec 21, 2018
Company News

Surface drops after deprioritizing lead product

...preclinical assets into clinical testing, with IND submissions for SRF617 and SRF388 slated for 4Q19. SRF617...
...and business operations on Dec. 17. Surface Oncology Inc. (NASDAQ:SURF), Cambridge, Mass. Business: Cancer Sandi Wong SRF231 SRF373 (NZV930) SRF388 SRF617 Novartis...
Read More
BioCentury | Dec 19, 2018
Company News

Surface drops after deprioritizing lead product

...preclinical assets into clinical testing, with IND submissions for SRF617 and SRF388 slated for 4Q19. SRF617...
...of finance to SVP of finance and business operations on Monday. Sandi Wong SRF231 SRF373 (NZV930) Novartis AG Surface Oncology Inc. CD47 Lymphoma SRF388 SRF617...
Read More
Items per page:
1 - 5 of 5